Amylyx Pharmaceuticals, Inc.
$17.57
▲
4.18%
2026-04-21 05:16:01
amylyx.com
NMS: AMLX
Explore Amylyx Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.03 B
Current Price
$17.57
52W High / Low
$18.61 / $3.79
Stock P/E
—
Book Value
$2.78
Dividend Yield
—
ROCE
-49.46%
ROE
-61.59%
Face Value
—
EPS
$-1.53
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
136
Beta
-0.21
Debt / Equity
1.95
Current Ratio
14.27
Quick Ratio
14.27
Forward P/E
-13.35
Price / Sales
—
Enterprise Value
$1.5 B
EV / EBITDA
-9.8
EV / Revenue
—
Rating
Strong Buy
Target Price
$22.8
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
| 2. | Assertio Holdings, Inc. | $18.14 | — | $116.08 M | — | -12.35% | -28.25% | $20.45 / $8.55 | $14.63 |
| 3. | BioCryst Pharmaceuticals, Inc. | $9.19 | 8.7 | $2.3 B | — | 107.2% | -88.68% | $11.31 / $6 | $-0.56 |
| 4. | Shuttle Pharmaceuticals Holdings, Inc. | $0.99 | — | $5.7 M | — | -791.36% | -7.91% | $11.25 / $0.5 | $1.13 |
| 5. | Aquestive Therapeutics, Inc. | $4.24 | — | $527.23 M | — | -62.98% | 178.61% | $7.55 / $2.12 | $-0.28 |
| 6. | Caring Brands, Inc. | $1.25 | — | — | — | -157.44% | -2.17% | $6 / $0.06 | $0.14 |
| 7. | Biofrontera Inc. | $1.09 | — | $12.81 M | — | -68.08% | -1.41% | $1.19 / $0.54 | $0.9 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | -0.67 M | — |
| Operating Profit | -36.6 M | -36.03 M | -42.86 M | -37.8 M | -40.65 M | — |
| Net Profit | -33 M | -34.39 M | -41.44 M | -35.91 M | -37.55 M | — |
| EPS in Rs | -0.3 | -0.31 | -0.37 | -0.32 | -0.34 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 87.37 M | 380.79 M | 22.23 M |
| Operating Profit | -153.29 M | -255.68 M | 38.8 M | -201.34 M |
| Net Profit | -144.74 M | -301.74 M | 49.27 M | -198.38 M |
| EPS in Rs | -1.31 | -2.73 | 0.45 | -1.79 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 332.64 M | 193.63 M | 517.45 M | 391.45 M |
| Total Liabilities | 27.39 M | 28.87 M | 84.02 M | 50.85 M |
| Equity | 305.26 M | 164.76 M | 433.43 M | 340.61 M |
| Current Assets | 323.67 M | 189.43 M | 464.67 M | 382.13 M |
| Current Liabilities | 22.69 M | 28.41 M | 82.04 M | 46.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -123.34 M | -167.65 M | 11.92 M | -179.87 M |
| Investing CF | 14.04 M | 75.65 M | 92.05 M | -238.99 M |
| Financing CF | 257.03 M | 0.35 M | 3.54 M | 431.79 M |
| Free CF | -123.48 M | -167.8 M | 10.68 M | -182.4 M |
| Capex | -0.14 M | -0.16 M | -1.24 M | -2.53 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -77.06% | 1612.94% | — | — |
| Earnings Growth % | -712.42% | 124.84% | — | — |
| Profit Margin % | -345.36% | 12.94% | -892.38% | — |
| Operating Margin % | -292.63% | 10.19% | -905.72% | — |
| Gross Margin % | -42.65% | 93.32% | 86.54% | — |
| EBITDA Margin % | -291.6% | 10.48% | -903.53% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.